CAS: 4166-53-4; 4-Methyldihydro-2H-Pyran-2,6(3H)-Dione

相似化合物

4160-82-1 185815-59-2 108-55-4

上下游产品

methanol 3-methyl glutaric acid 3-methylpentanedial malonic acid 5-(3,4-dimethoxy-phenyl)-3-methyl-5-oxo-valeric acid 3-methyl-1,5-pentanedioic acid monomethyl ester 4-methyl-1-phenethyl-piperidine-2,6-dione 3-methyl-glutaric acid bis-phenethylamide

3-甲基戊二酸置于乙酰氯体系中,化学反应 2.0H,反应生成 3-甲基戊二酸酐
参考文献:开发新型苯氧基烷基哌啶作为具有有效抗遗忘作用的高亲和力 Sigma-1 (σ1) 受体配体
标题:开发新型苯氧基烷基哌啶作为具有有效抗遗忘作用的高亲和力 Sigma-1 (σ1) 受体配体
摘要:Sigma-1 (σ 1) 受体在许多正常生理功能和病理疾病状态中发挥重要作用,因此代表了激动剂和拮抗剂的有吸引力的治疗靶点.在这里,我们描述了基于先导化合物 1-[ω-(4-氯苯氧基)乙基]-4-甲基哌啶 (1A) 的一系列新型苯氧基烷基哌啶,其中哌啶氮的α碳原子的甲基化程度是系统性的多变. σ 1和σ 2受体以及δ 8-δ 7甾醇异构酶(Si) 的亲和力范围为亚纳摩尔至微摩尔k I值.虽然在σ 1处显示出最高亲和力,但哌啶环甲基化程度的增加逐渐降低了亲和力.在两项记忆测试中,亚纳摩尔亲和力1A和 1-[ω-(4-甲氧基苯氧基)乙基]-4-甲基哌啶 (1B) 显示出与 σ 1受体激动相关的有效抗遗忘作用.自动受体-小分子配体对接为1A和1B的激动作用提供了基于分子结构的原理.总体而言,苯氧基烷基哌啶类具有开发高亲和力 σ 1受体激动剂的潜力,而化合物1A似乎是同类中最好的(迄今为止超过参考化合物
DOI:10.1016/j.Ejmech.2021.114038

专利信息

专利号:US-2023357257-A1
优先权日:2020-12-28
标 题 :Novel process for the synthesis of noroxymorphone from morphine
发明人：GORBACHEV DMITRY; LAM HON WAI; SAXENA AAKARSH; SAXENA NAVIN SATYAPAL
权利人:NAVIN SAXENA RESEARCH & TECH PVT LTD
摘要:The present invention relates to a novel, efficient, pot- and atom-economical, and industrially applicable process for converting morphine to noroxymorphone using reagents and solvents of lesser toxicity and lower cost with respect to those used in the prior art.

专利号:US-2009004396-A1
优先权日:2007-06-26
标题:Highly-Branched, Allyl Ether-Functionalized, Unsaturated Polyester Resins and Coating Compositions of the Same
发明人：WU SHAOBING; BRANDENBURGER LARRY; MELNYK THOMAS
权利人:VALSPAR CORP
摘要:The synthesis of highly-branched, allyl ether-functionalized, unsaturated polyester resins is disclosed herein, along with the utility of these resins in formulating formaldehyde-free, isocyanate-free, and styrene-free, low temperature and fast curing solvent-borne coatings, including wood coatings, and their use as alternatives for conventional acid catalyzed urea- or melamine-crosslinked coating systems.

专利号:WO-2025124564-A1
优先权日:2023-12-15
标题:Polyester synthesis based on aspartic acid modification
发明人：ZHANG KECHUN; CHEN XI; LEI TENGFEI; LIU SHENGYANG
权利人:MINT BIOTECHNOLOGIES CO LTD
摘要:Provided in the present invention is polyester synthesis based on aspartic acid modification. A monomer of a unique structure of an imide ring is obtained based on aspartic acid and a dibasic acid likely to be cyclized, the monomer is based on the aspartic acid, can be derived from biomass, is low in cost and renewable, meets the requirement of sustainable development, and the unique structure of the monomer can regulate and control various properties of polyester materials, such as the mechanics, temperature resistance, hydrophilicity and hydrophobicity, and crystallization.

专利号:US-6326372-B1
优先权日:1999-09-30
标 题:Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
发明人：EVANS BEN E; GILBERT KEVIN F
权利人:MERCK & CO INC
摘要:Lactam and cyclic urea derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:CA-3200832-A1
优先权日:2020-12-28
标 题:Novel process for the synthesis of noroxymorphone from morphine

专利号:US-8592458-B2
优先权日:2005-06-07
标 题 :Alpha7 nicotinic receptor selective ligands
发明人：KEM WILLIAM READE; SOTI FERENC
权利人:KEM WILLIAM READE; SOTI FERENC; UNIV FLORIDA
摘要:The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.